1. 1181. Use of the Combination Antibiogram in the Era of MDR Gram-Negative Pathogens. (26th November 2018) Authors: Klinker, Kenneth; Cherabuddi, Kartikeya; Redell, Mark; Balogh, Matthew; Massey, Jill; Dudley, Michael Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S357 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1928. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting. (26th November 2018) Authors: Lodise, Thomas; Packnett, Elizabeth; Armstrong, Shannon; Redell, Mark Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 338Prevalence, Mortality and Outcomes of Antibiotic Therapy of Multi-Drug Resistant Acinetobacter baumannii. (December 2014) Authors: Lapensee, Kenneth T.; Fan, Weihong; Redell, Mark; Dudley, Michael; Loutit, Jeff Journal: Open forum infectious diseases Issue: Volume 1(2014)Supplement 1 Page Start: S136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program. (19th March 2018) Authors: Redell, Mark; Moeck, Greg; Lucasti, Christopher; Durso, Stephanie; Kennedy, Cynthia; Fusaro, Karen; Loutit, Jeff; Dudley, Michael Journal: Open forum infectious diseases Issue: Volume 5:Number 6(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Antimicrobial Management of Respiratory Infections in Severe Acute Respiratory Syndrome Coronavirus 2 Patients: Clinical and Antimicrobial Stewardship Programs Conundrums. (26th October 2020) Authors: Goldstein, Ellie J C; Tillotson, Glenn; Redell, Mark Journal: Open forum infectious diseases Issue: Volume 7:Number 11(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials. (19th January 2017) Authors: Lodise, Thomas P.; Redell, Mark; Armstrong, Shannon O.; Sulham, Katherine A.; Corey, G. Ralph Journal: Open forum infectious diseases Issue: Volume 4:Number 1(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties. (23rd March 2022) Authors: Hoover, Randall K; Krsak, Martin; Molina, Kyle C; Shah, Kairav; Redell, Mark Journal: Open forum infectious diseases Issue: Volume 9:Number 5(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Minocycline Intravenous for the Treatment of Serious Infections Due to Gram-Negative Nonpseudomonal Bacteria, Including Stenotrophomonas maltophilia, Acinetobacter baumannii, and Burkholderia cepacia. Issue 4 (July 2020) Authors: Sierra-Hoffman, Miguel; Redell, Mark; Benefield, Russell; Caruso, Patricia; Estrada, Sandy; Leuthner, Kimberly; Zappas, Kristie; Kennedy, Cynthia; Massey, Jill Journal: Infectious diseases in clinical practice Issue: Volume 28:Issue 4(2020:Jul.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗